ByTrending Posts
Can Mandolin’s $40M VC Boost End Insurance Delays…
Key Highlights: AI-Driven Innovation Tackling a Complex Healthcare BarrierSpecialty medications for cancer and neurodegenerative diseases often require authorization…
Will Sanofi’s AI Ethics Revolution Trigger a $100…
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Is Thermo Fisher’s $10B Q2 Surge the Inflection…
Key Highlights Financial Resilience and Strategic MarginsThermo Fisher Scientific’s Q2 2025 report showcases its fortress-like financial discipline. With…
Can IGC Pharma’s New AI Models Change Alzheimer’s…
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Cedars-Sinai’s CS Connect Revolutionize Virtual Care? 42,000…
Key Takeaways: AI helping doctors focus on care, not paperworkCedars-Sinai launched CS Connect to improve access to care…
Can hellocare.ai and Epic’s Native Integration Redefine AI-Driven…
Key Takeaways Epic Integration Enhances Bedside Engagementhellocare.ai’s purpose-built virtual care device now supports Epic MyChart Bedside TV out…
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape…
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma…
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven…
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Trending Posts
Latest Stories
Will Merck’s $9.2 Billion Acquisition of Cidara Therapeutics Reshape the Future of Long-Acting Influenza Prevention?
Rahway, NJ & San Diego, CA | January 2026 Merck & Co., Inc. has confirmed…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed…
Is AI Now Shaping the Future of Biopharma R&D — and Who’s Leading the Transformation?
Executive Summary A recent Endpoints Signal Pulse Report reveals that half of biopharma professionals now…
Is Butterfly Network Using AI and Handheld Imaging to Democratize Diagnostics and Transform Patient Care?
Executive Summary Butterfly Network is pioneering AI-enabled, handheld ultrasound devices designed to make imaging more…
Gallery
